StocksMedium•25 September 2026•
1 min read
Jury Awards Nektar $90 Million in Legal Dispute Against Eli Lilly
Key Facts
1A jury awarded Nektar $90 million plus interest in a trial against Eli Lilly.
2Nektar shares gained 5% following the jury's decision.
A jury awarded Nektar Therapeutics $90 million plus interest in a legal trial against Eli Lilly and Company. Seeking Alpha reported that the jury found Eli Lilly liable for breaching an implied covenant of good faith and fair dealing regarding their former collaboration on rezpegaldesleukin. Nektar shares gained 5% following the announcement of the verdict.
LLY closed at $1181.89 on September 24, 2026, prior to the jury's decision. While the $90 million award represents a significant legal outcome, the financial impact is considered relatively small relative to Eli Lilly's mega-cap valuation.